Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KC-4702

TMD8-BTK-V416L-KI-1A3 Cell Line

Home » TMD8-BTK-V416L-KI-1A3 Cell Line

Background of TMD8-BTK-V416L-KI-1A3 Cell Line

BTK-V416L is a specific mutation found in the Bruton's tyrosine kinase (BTK) gene, which encodes a member of the Tec family of non-receptor tyrosine kinases. BTK plays a critical role in B-cell development, activation, and survival by transducing signals from the B-cell receptor (BCR) to downstream effectors. The V416L mutation involves the substitution of valine for leucine at position 416 within the kinase domain of BTK, potentially altering its senzymatic activity and substrate specificity.Studies have shown that the BTK-V416L mutation can result in a conformational change in the kinase domain, affecting both the binding affinity of ibrutinib and the catalytic efficiency of BTK. This alteration can lead to sustained BCR signaling despite the presence of the inhibitor, contributing to disease progression. Understanding the molecular mechanisms underlying this resistance is crucial for developing alternative therapeutic strategies for patients who develop resistant mutations.

Specifications

Catalog Number:
KC-4702
Cell Line Name:
TMD8-BTK-V416L-KI-1A3 Cell Line
Clone Number
Host Cell Line:
TMD8
Description:
Stable TMD8 clone expressing endogenous BTK gene bearing A428D mutations, No.1B4
Quantity:
Two vials of frozen cells (2-5×106/vial)
Stability:
Stable in culture over a minimum of 10 passages
Application:
Drug screening and biological assays
Freezing Medium:
70% RPMI1640+20% FBS+10% DMSO
Propagation Medium:
RPMI1640+10% FBS
Selection Marker:
N/A
Morphology:
lymphoblast
Subculture:
Split saturated culture 1:3-1:6 every 2-3 days; seed out at about 1-3 × 105 cells/mL
Incubation:
37 °C with 5% CO2
Storage:
Liquid nitrogen immediately upon receiving
Doubling Time:
Approximately 30 hours
Mycoplasma Status:
Negative
In Vivo Validation:

Cell Line Generation

TMD8-BTK-V416L-KI-1A3 cell line was generated using the CRISPR method.

Characterization

Figure 1: Characterization of TMD8-BTK-V416L-KI-1A3 cell line stable clone using PCR sequencing.

Figure 2: Characterization of TMD8-BTK-V416L-KI-1A3 cell line stable clone using RT-PCR sequencing.

Figure 3. Characterization of dose-response curves for BTK inhibitors on TMD8 and TMD8-BTK-V416L-KI-1A3 cells.

Cell Resuscitation

1. Prewarm culture medium (RPMI1640 + 10% FBS)in a 37°C water bath.
2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
7. Incubate the flask at 37°C, 5% CO2 incubator.
8. Split saturated culture 1:3-1:6 every 2-3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

1. Prepare the freezing medium (70% RPMI1640 + 20% FBS + 10% DMSO) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.
3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
6. Aliquot 1 mL of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
8. Transfer vials to liquid nitrogen for long-term storage.

References

1.Woyach, J. A., et al. (2014). Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.New England Journal of Medicine, 370(25), 2286-2294. https://doi.org/10.1056/NEJMoa1400077
2.Brown, J. R., et al. (2016). Preclinical characterization of acalabrutinib (ACP-196): a next-generation selective Bruton tyrosine kinase inhibitor.Cancer Discovery, 6(3), 325-334. https://doi.org/10.1158/2159-8290.CD-15-0828
3.Kahl, B. S., et al. (2017). Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: interim analysis results of an open-label, phase 3 trial.The Lancet Oncology, 18(8), 1017-1028. https://doi.org/10.1016/S1470-2045(17)30429-5